流感疫苗整群随机对照试验中复合结局指标的应用
该研究利用加拿大Hutterite社区三项盲法整群随机对照试验的儿童流感疫苗接种数据,评估由抗菌药物处方、学校或工作缺勤及呼吸系统疾病就医构成的复合结局。结果显示复合结局可提高事件率与估计精度,但其保护效应在不同试验中与各组分指标存在差异。作者认为复合结局是提高流感疫苗试验事件率与精度的可行方法,值得进一步探索。
要点
- 复合结局可提高流感疫苗整群随机试验的事件率与估计精度。
- 复合结局的保护效应在不同试验中与各组分指标存在差异。
- 复合结局在流感疫苗试验中的应用价值需进一步研究。
核心结论
- 复合结局可作为提高流感疫苗试验事件率与估计精度的可行方法,应在本领域进一步探索。
研究设计与样本
- 利用加拿大Hutterite社区三项盲法整群随机对照儿童流感疫苗接种试验的数据进行分析。
- 复合结局由抗菌药物处方、学校或工作相关缺勤及呼吸系统疾病就医构成。
- 比较复合结局与各组分结局的比值降低、频率及置信区间。
主要发现
- 试验1中,复合结局的事件率、显著性、精度及保护效应均优于其组分。
- 试验2中,复合结局事件率更高、精度优于三分之二的组分,但显著性更低且保护效应为零。
- 试验3中,复合结局事件率更高但保护效应弱于其组分,精度与显著性无显著差异。
临床怎么用
- 在流感疫苗整群随机试验设计时,可考虑采用复合结局以提高事件率和估计精度。
- 解读复合结局结果时需注意其保护效应可能与各组分指标不一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite being widely used in other fields, composite outcomes are seldom used in influenza vaccine randomized trials. Vaccine trialists may benefit from the increased event rates and power of composite outcomes. We explored the use of a composite outcome on a series of randomized control trials conducted within Canadian Hutterite communities. METHODS: Using data from three blinded, cluster randomized control trials of pediatric influenza vaccination, we assessed the use of a composite outcome of antimicrobial prescription, school or work-related absenteeism, and medically attended visits for respiratory illness. Key comparisons between component outcomes and the composite included odds reduction, frequency, and confidence intervals. RESULTS: In Trial 1, 65 Hutterite colonies were randomly assigned to receive either the influenza vaccine or the hepatitis A vaccine. Among all season 1 and 3 participants in Trial 1, the composite outcome yielded a greater event rate, significance, precision, and a greater protective effect than its components. Within participants across all seasons in Trial 2, the composite yielded a greater event rate, lower significance, a null protective effect, and greater precision than two out of three of its components. Among all participants across all seasons in Trial 3, the composite outcome yielded a greater event rate and a weaker protective effect than its components, with no notable differences in precision or significance. CONCLUSIONS: Composite outcomes can be a viable approach to raise event rates and increase the precision of estimates in influenza vaccine trials and should be explored further within this field.
引用
- Cheng K, Pullenayegum E, Singh P, et al. Use of composite outcomes in cluster randomized control trials of influenza vaccines. Vaccine. 2026. PMID: 41534484. doi:10.1016/j.vaccine.2026.128224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。